Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures~* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening~* No prior use of any approved or investigational antiretroviral drug for any length of time, except the use for pre-exposure prophylaxis (PREP) or post-exposure prophylaxis (PEP), up to 6 months prior to screening~* Screening genotype report must show sensitivity to elvitegravir, emtricitabine, tenofovir disoproxil fumarate (tenofovir DF)~* Normal electrocardiogram (ECG)~* Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the Cockcroft-Gault formula for creatinine clearance~* Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin~* Adequate hematologic function~* Serum amylase ≤ 5 × ULN~* Males and females of childbearing potential must agree to utilize highly effective contraception methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following the last dose of study drug~* Females who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing~* Females who have stopped menstruating for ≥ 12 months but do not have documentation of ovarian hormonal failure must have a serum follicle stimulating hormone (FSH) level at screening within the post-menopausal range based on the Central Laboratory reference range~Key Exclusion Criteria:~* A new acquired immunodeficiency syndrome (AIDS) defining condition diagnosed within the 30 days prior to screening~* Hepatitis B surface antigen (HBsAg) positive~* Hepatitis C antibody positive~* Individuals experiencing decompensated cirrhosis~* Females who are breastfeeding~* Positive serum pregnancy test~* Have an implanted defibrillator or pacemaker~* Current alcohol or substance use judged by the Investigator to potentially interfere with study compliance~* History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline~* Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements~* Participation in any other clinical trial (including observational trials) without prior approval~* Individuals receiving ongoing therapy with drugs not to be used with elvitegravir, cobicistat, emtricitabine, tenofovir DF, and TAF or individuals with any known allergies to the excipients of E/C/F/TDF or E/C/F/TAF single-tablet regimen tablets~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E/C/F/TAF (Double-Blind Phase) (Type: EXPERIMENTAL): E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
- E/C/F/TDF (Double-Blind Phase) (Type: ACTIVE_COMPARATOR): E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
- Open-Label Extension Phase (Type: EXPERIMENTAL): After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.

Based on this trial design, predict the completion outcome and termination type (if applicable).